/
CRBU
$1.61-$0.09 (-5.29%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$168.6M
99M shares
52-week range
$1.38 – $3.54
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-24.87
Caribou Biosciences, Inc. Common Stock
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
www.cariboubio.com- Employees
- 97
- IPO / List date
- Jul 23, 2021
- HQ
- BERKELEY, CA
Held by traders on TradeandTell
No one on the platform currently holds CRBU.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,590,497 | $4.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRBU yet.
